Royalty Pharma (NASDAQ:RPRX) EVP Sells $767,600.00 in Stock

Royalty Pharma PLC (NASDAQ:RPRX) EVP Marshall Urist sold 20,000 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $38.38, for a total value of $767,600.00. Following the completion of the sale, the executive vice president directly owned 120,000 shares of the company’s stock, valued at $4,605,600. The trade was a 14.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Marshall Urist also recently made the following trade(s):

• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.32, for a total value of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total value of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.15, for a total value of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The stock was sold at an average price of $39.93, for a total value of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Stock Up 0.7%

RPRX stock traded up $0.26 during midday trading on Monday, reaching $38.86. 2,161,744 shares of the company’s stock traded hands, compared to its average volume of 4,332,750. Royalty Pharma PLC has a 52 week low of $24.46 and a 52 week high of $41.24. The company has a market cap of $22.43 billion, a price-to-earnings ratio of 29.44, a P/E/G ratio of 2.03 and a beta of 0.47. The firm’s fifty day moving average price is $38.36 and its 200-day moving average price is $36.79. The company has a quick ratio of 3.48, a current ratio of 3.48 and a debt-to-equity ratio of 0.89.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the consensus estimate of $1.11 by $0.06. Royalty Pharma had a net margin of 32.51% and a return on equity of 26.36%. The company had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. As a group, sell-side analysts forecast that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Wednesday, December 10th. Investors of record on Friday, November 14th were given a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend was Friday, November 14th. Royalty Pharma’s dividend payout ratio is presently 66.67%.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in RPRX. Nordea Investment Management AB grew its holdings in Royalty Pharma by 603.9% in the 2nd quarter. Nordea Investment Management AB now owns 655,995 shares of the biopharmaceutical company’s stock worth $23,701,000 after acquiring an additional 562,799 shares during the last quarter. Watchtower Advisors LP bought a new stake in shares of Royalty Pharma in the second quarter worth about $3,603,000. Creative Planning increased its holdings in Royalty Pharma by 22.7% during the 2nd quarter. Creative Planning now owns 52,553 shares of the biopharmaceutical company’s stock valued at $1,893,000 after purchasing an additional 9,718 shares during the period. Cookson Peirce & Co. Inc. raised its position in Royalty Pharma by 55.1% during the 2nd quarter. Cookson Peirce & Co. Inc. now owns 34,263 shares of the biopharmaceutical company’s stock valued at $1,234,000 after purchasing an additional 12,171 shares during the last quarter. Finally, Monetta Financial Services Inc. purchased a new stake in Royalty Pharma in the 2nd quarter worth approximately $1,081,000. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on RPRX shares. Wall Street Zen lowered shares of Royalty Pharma from a “strong-buy” rating to a “buy” rating in a research report on Friday, November 28th. The Goldman Sachs Group started coverage on Royalty Pharma in a report on Tuesday, September 30th. They issued a “buy” rating and a $42.00 target price for the company. Cowen reiterated a “buy” rating on shares of Royalty Pharma in a report on Thursday, December 11th. Weiss Ratings cut Royalty Pharma from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Saturday, October 25th. Finally, TD Cowen boosted their price target on shares of Royalty Pharma from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $45.60.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.